On this page
HYDROCORTISONE VALERATE
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Hydrocortisone Valerate | 2 mg/g | 1370754 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 210307-001 | HYDROCORTISONE VALERATE | CREAM | HYDROCORTISONE VALERATE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | August 15, 2019 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251113). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Hydrocortisone valerate cream USP, 0.2% is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Hydrocortisone valerate cream USP, 0.2% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Hydrocortisone valerate cream USP, 0.2% should not be used with occlusive dressings unless directed by a physician. Hydrocortisone valerate cream USP, 0.2% should not be applied in the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hydrocortisone valerate cream USP, 0.2% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies involving pediatric patients one month to 2 years of age (n=29), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 21%. Reported reactions included stinging (10%), eczema (7%), fungal infection (3%), and gastrointestinal disorder (3%). In controlled clinical studies involving pediatric patients 2 to 12 years of age (n=153), the incidence of adverse experiences, regardless of relationship to the use of hydrocortisone valerate cream USP, 0.2%, was approximately 10%. Reported reactions included stinging (3%), burning skin (2%), infection (Body as a Whole) (2%). Skin irritation, eczema, pruritus, application site reaction, rash, rash maculopapular, and dry skin were all reported at incidences of approximately 1%. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Hydrocortisone valerate cream USP, 0.2% contains hydrocortisone valerate, 11,2l-dihydroxy-17-[(l-oxopentyl)oxy]-(11β)-pregn-4-ene-3,20-dione, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, hydrocortisone valerate is C 26 H 38 O 6 . It has the following structural formula: Hydrocortisone valerate has a molecular weight of 446.58. It is a white to off white, crystalline powder, soluble in ethanol, chloroform and acetone, slightly soluble in isopropanol and insoluble in water. Each gram of hydrocortisone valerate cream USP, 0.2% contains 2mg hydrocortisone valerate in a hydrophilic base composed of carbomer 980, dibasic sodium phosphate, methylparaben, polyoxyl 2 stearyl ether, propylene glycol, purified water, sodium lauryl sulfate, steareth-100, stearyl alcohol and white petrolatum. chem-structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied hydrocortisone valerate cream USP, 0.2% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Hydrocortisone valerate cream USP, 0.2%, is supplied in 15 g (NDC 68180-954-01), 45 g (NDC 68180-954-02) and 60 g (NDC 68180-954-03) tube sizes. Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. LUPIN and the are registered trademarks of Lupin Pharmaceuticals, Inc. Image
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 0713-0720-15 | 0713-0720 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0720-15) / 15 g in 1 TUBE | July 1, 2021 |
| 0713-0720-37 | 0713-0720 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0720-37) / 45 g in 1 TUBE | July 1, 2021 |
| 0713-0720-60 | 0713-0720 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0720-60) / 60 g in 1 TUBE | July 1, 2021 |
| 68180-954-01 | 68180-954 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-954-01) / 15 g in 1 TUBE | November 19, 2019 |
| 68180-954-02 | 68180-954 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-954-02) / 45 g in 1 TUBE | November 19, 2019 |
| 68180-954-03 | 68180-954 | Lupin Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68180-954-03) / 60 g in 1 TUBE | November 19, 2019 |
| 51672-1290-1 | 51672-1290 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1290-1) / 15 g in 1 TUBE | August 25, 1998 |
| 51672-1290-3 | 51672-1290 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1290-3) / 60 g in 1 TUBE | August 25, 1998 |
| 51672-1290-6 | 51672-1290 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1290-6) / 45 g in 1 TUBE | August 25, 1998 |
| 0713-0720 | 0713-0720 | Cosette Pharmaceuticals, Inc. | — | July 1, 2021 |
| 68180-954 | 68180-954 | Lupin Pharmaceuticals, Inc. | — | November 19, 2019 |
| 51672-1290 | 51672-1290 | Sun Pharmaceutical Industries, Inc. | — | August 25, 1998 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.